Ingevity, Corp. (NGVT)
NYSEMaterialsChemicals - SpecialtySnapshot 2026-09-09
$68.10-1.52%
Close 2026-09-09 · 1-day change
NYSEMaterialsChemicals - SpecialtySnapshot 2026-09-09
Intact: The reason to own it still holds.
Ingevity steadily grows revenue near $1.1 billion in 2026. Profit stays strong with adjusted EBITDA around $370 million. The company improves earnings per share to about $4.7-$5.2. Free cash flow supports reducing debt to a safer level.
Revenue and earnings could fall below guidance due to portfolio changes and market headwinds. Profit margins may shrink, and leverage reduction could stall. This would pressure cash flow and valuation.
The price is about 16% below our fair value near $89. Analysts expect about 3% revenue decline, while we see stable revenue and margin targets. The market fairly prices in current challenges but may underestimate management's execution.
Breaks if: Adjusted EPS falls below $4.70 in FY26
Deliver full year adjusted diluted EPS between $4.70 and $5.45 for 2026.
Stated as a priority in 3 of last 3 quarters. Management raised adjusted EPS guidance from $4.70-$5.20 in 2026-Q1 to $5.00-$5.45 in 2026-Q2. Diluted adjusted EPS was $1.74 in 2026-Q2, up from $1.22 year-over-year, showing progress toward the full-year target. The trajectory is delivering.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story in the Materials sector. The current thesis state is cautious, as management has set ambitious revenue and earnings targets while navigating a competitive landscape.
The market appears to have priced in some expectations of growth, as indicated by a stretched valuation compared to peers. However, there is a low fragility tier, suggesting that the stock is not overly sensitive to negative news.
Fundamentals are likely to improve, given management's strong focus on achieving revenue and EBITDA targets. The recent financial performance has shown a recovery, but there is still a moderate risk due to the industry's high miss rate.
The thesis hinges on management's ability to meet or exceed their guidance without cutting it, as well as external factors like inflation and sector performance. Positive earnings from sector leaders could also bolster NGVT's momentum.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Raises full-year diluted adjusted EPS guidance to a range of $5.00 to $5.45”
“It expects adjusted EPS of $4.70 to $5.20”
“adjusted EPS between $4.80 to $5.20”
Breaks if: Net leverage remains above 2.5x at end of FY26
Utilize strong free cash flow to reduce net leverage to within 2.0 to 2.5 times by year-end 2026.
Stated as a priority in 3 of last 3 quarters. Net leverage improved from 3.0 times in 2025-Q2 to 2.5 times in 2026-Q2. Management plans to use free cash flow, which is guided between $220 million and $245 million for 2026, to reduce leverage further to the 2.0-2.5x target range. The trajectory shows delivering progress on leverage reduction.
“Net leverage improved to 2.5 times versus the first quarter of 2026”
“Net leverage held steady at 2.6 times versus the fourth quarter of 2025”
“Net leverage improved to 2.6 times from 3.0 times a year ago”
Breaks if: Divestitures not completed or reversed by mid-2026
Continue portfolio transformation by divesting non-core businesses such as Road Markings and Industrial Specialties.
Stated as a priority in 3 of last 3 quarters. Management completed divestitures of Road Markings in April 2026 and Industrial Specialties in January 2026, aligning the portfolio with core capabilities. These actions support the strategic focus and are reflected in adjusted revenue and EBITDA guidance excluding divested lines. The trajectory shows delivering on portfolio sharpening.
“Completed the sale of Road Markings product line on April 15, 2026”
“Completed sale of North Charleston refinery assets and Industrial Specialties product line on January 1, 2026”
“Concluded portfolio review and initiated exploration of strategic alternatives for Advanced Polymer Technologies and Road Markings”
Breaks if: Adjusted EBITDA falls below $370 million in FY26
Breaks if: Revenue falls below $1.05 billion in FY26
Deliver full year 2026 net sales between $1.05 billion and $1.15 billion, adjusted for divestitures.
Stated as a priority in 3 of last 3 quarters. Management raised full-year 2026 net sales guidance from $1.1-$1.2 billion in 2025-Q4 to $1.05-$1.15 billion in 2026-Q1 and reaffirmed it in 2026-Q2 after divesting Road Markings. Revenue in 2026-Q2 was $314.1 million, down 5% year-over-year due to divestiture but up 5% excluding it. The trajectory shows management delivering on this revenue guidance with adjustments for portfolio changes.
“It now expects full year 2026 net sales between $1.05 billion and $1.15 billion”
“It expects full year 2026 net sales between $1.05 billion and $1.15 billion”
“The company expects full year 2026 net sales between $1.1 billion and $1.2 billion”
Overall, NGVT's trajectory looks promising, but it remains sensitive to execution and market conditions. Not investment advice.